ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis

Kidney and Blood Pressure Research

Volumn 36, Issue 1, 2012, Pages 200-208

  Tanhäuserová, Veronika ^a,c   Tomandl, Josef ^b   Pácal, Lukáš ^a   Klepárník, Martin ^b   Malúšková, Denisa ^c   Bartáková, Vendula ^a   Kuricová, Katarína ^a   Řehořová, Jitka ^d   Štěpánková, Soňa ^d   Svojanovský, Jan ^e   Olšovský, Jindy̌ich ^e   Bělobrádková, Jana ^d   Krusová, Darja ^e   Jurajda, Michal ^a   Mužík, Jan ^c   Pavlíkc, Tomáš ^c   Kaņková, Kateřina ^a  

^a Dept of Pathophysiology ^*  (Czech Republic)

^b Faculty of Medicine   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Asymmetric dimethylarginine; Competing risk analysis; Diabetic nephropathy; Dimethylarginine dimethylaminohydrolase; Polymorphism; Symmetric dimethylarginine

Indexed keywords

ARGININE; CREATININE; DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE;

ADULT; ALBUMINURIA; ARTICLE; BLOOD LEVEL; CAUCASIAN; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AMIDOHYDROLASES; ARGININE; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84868607144     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000343409     Document Type: Article

References (42)

1. Siervo M, Corander M, Stranges S, Bluck L: Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: The putative role of asymmetric dimethylarginine (adma). Nutr Metab Cardiovasc Dis 2011;21:1-10.
2. Teerlink T, Luo Z, Palm F, Wilcox CS: Cellular adma: Regulation and action. Pharmacol Res 2009;60:448-460.
3. Palm F, Onozato ML, Luo Z, Wilcox CS: Dimethylarginine dimethylaminohydrolase (ddah): Expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007;293:H3227-3245.
4. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343:209-214.
5. Jones LC, Tran CT, Leiper JM, Hingorani AD, Vallance P: Common genetic variation in a basal promoter element alters ddah2 expression in endothelial cells. Biochem Biophys Res Commun 2003;310:836-843.
6. Maas R, Erdmann J, Luneburg N, Stritzke J, Schwedhelm E, Meisinger C, Peters A, Weil J, Schunkert H, Boger RH, Lieb W: Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol Res 2009;60:488-493.
7. Caplin B, Nitsch D, Gill H, Hoefield R, Blackwell S, MacKenzie D, Cooper JA, Middleton RJ, Talmud PJ, Veitch P, Norman J, Wheeler DC, Leiper JM: Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by ddah1 polymorphisms. Kidney Int 2010;77:459-467.
8. Abhary S, Burdon KP, Kuot A, Javadiyan S, Whiting MJ, Kasmeridis N, Petrovsky N, Craig JE: Sequence variation in ddah1 and ddah2 genes is strongly and additively associated with serum adma concentrations in individuals with type 2 diabetes. PLoS One, DOI: 10.1371/journal.pone.0009462.
9. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-2074.
10. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strodter D, Simon BC, Mugge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Boger RH: Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter coronary artery risk determination investigating the influence of adma concentration (cardiac) study. Am Heart J, DOI: 10.1016/j.ahj.2006.06.005.
11. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-2128.
12. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-658.
13. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Jama 2002;287:1420-1426.
14. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-1203.
15. Krzyzanowska K, Mittermayer F, Shnawa N, Hofer M, Schnabler J, Etmuller Y, Kapiotis S, Wolzt M, Schernthaner G: Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 2007;24:81-86.
16. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB: Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007;92:1881-1885.
17. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
18. Jacobi J, Tsao PS: Asymmetrical dimethylarginine in renal disease: Limits of variation or variation limits? A systematic review. Am J Nephrol 2008;28:224-237.
19. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 2005;16:2449-2455.
20. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001;358:2113-2117.
21. Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, Bengtsson C, Bjorkelund C, Thelle D: Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in gothenburg. Arterioscler Thromb Vasc Biol 2008;28:961-967.
22. Wolf C, Lorenzen JM, Stein S, Tsikas D, Stork S, Weidemann F, Ertl G, Anker SD, Bauersachs J, Thum T: Urinary asymmetric dimethylarginine (adma) is a predictor of mortality risk in patients with coronary artery disease. Int J Cardiol 2012;156:289-294.
23. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461.
24. Anderssohn M, Schwedhelm E, Luneburg N, Vasan RS, Boger RH: Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: An intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010;7:105-118.
25. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P: Plasma concentration of asymmetric dimethylarginine (adma) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008;31:747-752.
26. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G: Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007;30:1834-1839.
27. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-769.
28. Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, Ishii A, Iwamoto Y: Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2009;24:1884-1888.
29. Kiechl S, Lee T, Santer P, Thompson G, Tsimikas S, Egger G, Holt DW, Willeit J, Xu Q, Mayr M: Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009;205:261-265.
30. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D: Symmetric dimethylarginine (sdma) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 2006;21:2446-2451.
31. de Jong S, Teerlink T: Analysis of asymmetric dimethylarginine in plasma by hplc using a monolithic column. Anal Biochem 2006;353:287-289.
32. Consortium TIH: The international hapmap project. Nature 2003;426:789-796.
33. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989.
34. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics 1988;16:1141-1154.
35. Fine JP GR: A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999;94:496-509.
36. Carter KW, McCaskie PA, Palmer LJ: Jlin: A java based linkage disequilibrium plotter. BMC Bioinformatics 2006;7:60.
37. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP: Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987-992.
38. Fogarty RD, Abhary S, Javadiyan S, Kasmeridis N, Petrovsky N, Whiting MJ, Craig JE, Burdon KP: Relationship between ddah gene variants and serum adma level in individuals with type 1 diabetes. J Diabetes Complications 2012;26:195-198.
39. Kankova K, Stejskalova A, Pacal L, Tschoplova S, Hertlova M, Krusova D, Izakovicova-Holla L, Beranek M, Vasku A, Barral S, Ott J: Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach. Diabetologia 2007;50:990-999.
40. Aucella F, Maas R, Vigilante M, Tripepi G, Schwedhelm E, Margaglione M, Gesualdo L, Boeger R, Zoccali C: Methylarginines and mortality in patients with end stage renal disease: A prospective cohort study. Atherosclerosis 2009;207:541-545.
41. Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS: Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-1600.
42. Gad MZ, Hassanein SI, Abdel-Maksoud SM, Shaban GM, Abou-Aisha K: Association of ddah2 gene polymorphism with cardiovascular disease in egyptian patients. J Genet 2011;90:161-163.